308 results
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
13 Aug 20
Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer
4:26pm
brings to Myriad Genetics more than three decades of executive leadership and business transformation experience in healthcare across a variety … of healthcare segments.
“Paul is an exceptional leader and executive with extraordinary passion, vision, experience, and operational skills,” said S. Louise
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
15 Oct 20
Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate
7:18am
Genetics. “By the end of this year, two-thirds of our board will consist of new members who bring deep healthcare and technology expertise spanning payer … is now positioned to advance its leadership in the healthcare industry.”
Board Membership
Since the fall of 2019, Myriad has added six new members
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
4 Jan 19
Regulation FD Disclosure
4:05pm
prescription drug claims data from 13,048 patients 21
Union Health Service Healthcare Utilization Study Red-bin patients had4-fold more disability … -bin patients, red-bin patients had 67% more general medical visits* (p = 0.039) 69% more total healthcare visits** (p = 0.014) Healthcare-related cost
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
14 Dec 21
Departure of Directors or Certain Officers
4:13pm
to their full potential, and implementing operational efficiencies to better serve patients and healthcare providers. “Nicole is a proven leader with a deep … ,” said Diaz. “She has a unique combination of business, healthcare and operational experience coupled with strong leadership qualities and expertise
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
28 May 20
Departure of Directors or Certain Officers
7:05am
March 2020.
“It has been a privilege to play a part of Myriad’s journey in becoming a leader in providing trusted healthcare advice to patients … molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives
8-K
EX-99.1
966nr91wdq0 ruih
25 Sep 19
Departure of Directors or Certain Officers
4:20pm
8-K
EX-99.1
fc9k 245a5r
10 Sep 20
Myriad Genetics Expands Board of Directors with New Member
7:24am
DEFA14A
1jq8ph8wc8ki9lor2df
15 Oct 20
Additional proxy soliciting materials
7:20am
8-K
EX-99.1
iauh01ds1kfwo2 qcofh
22 Jul 20
Departure of Directors or Certain Officers
7:15am
8-K
EX-99.1
kkh1uya i9ryu
24 May 21
Myriad Genetics Signs Definitive Agreement to Sell
7:05am
8-K
EX-99.1
ivyyeh1qe8pjtqqa
23 Mar 20
Myriad Announces Board of Directors Leadership Transition
7:16am
8-K
EX-99.1
ulphopj1r 6epvj4qdo7
3 Aug 21
Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans
7:05am
8-K
EX-99.1
51ofo1ge
2 Nov 21
Continues Strong Execution of Strategic Growth & Transformation Plans
8:40am
8-K
EX-99.1
8hetdbgr05v476
14 Aug 20
Myriad Genetics Announces Inducement Awards
4:18pm
8-K
EX-99.1
9pq8nwo 584e7
14 Mar 19
Myriad’s myPath® Melanoma Test Receives Medicare Coverage
8:52am
8-K
EX-99.1
q2ib6yr
21 Dec 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-99.1
5ih7v
1 Aug 18
Myriad Announces Closing of Counsyl Acquisition
12:00am
8-K
EX-99.1
fpo9y
9 Nov 20
Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter
8:02am
8-K
EX-99.1
kw8k 49ojhoqlyy4b
8 Apr 20
Regulation FD Disclosure
9:14am